No profile data available.
Whitehawk Therapeutics, Inc. (WHWK) is a healthcare company in the additional cancer treatment drugs industry, based in Morristown, United States, with about 32 full-time employees.
It reported revenue of $7.15 million for fiscal year 2025, down 72.5% from fiscal year 2024, and net income of -$20.60 million. Its market capitalization was $200.67 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021.
Whitehawk Therapeutics reported $7.15 million in revenue for fiscal year 2025, down 72.5% from $25.98 million in fiscal year 2024.
$200.67 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include MacroGenics, Inc. (MGNX), Sutro Biopharma, Inc. (STRO), Compugen Ltd. (CGEN), Corbus Pharmaceuticals Holdings, Inc. (CRBP).